Patients with resectable glioblastoma undergo upfront surgery followed by adjuvant radiotherapy plus chemotherapy. This approach implies a period of approximately 4–6 weeks between surgery and the start of adjuvant therapy in which the patient receives no active treatment. In this Perspective, the authors describe the potential of local therapies targeting the tumour resection margin that can be administered during this time window, including biological feasibility, the potential role of nanomedicines and various technical and regulatory challenges that will need to be addressed before clinical implementation becomes feasible.
- Thomas Kisby
- Gerben R. Borst
- Kostas Kostarelos
